Lewin I G, Papapoulos S E, O'Riordan J L
Clin Endocrinol (Oxf). 1977 Dec;7 Suppl:203s-207s. doi: 10.1111/j.1365-2265.1977.tb03382.x.
Normocalcaemia was restored and maintained in eleven hypoparathyroid and two pseudohypoparathyroid patients treated for up to 36 months with 1alpha-hydroxyvitamin D3. It was found to be a potent compound, maintenance doses ranging from 4 microgram weekly to 2 microgram daily. Supplementary oral calcium was used in acutely and profoundly hypocalcaemic patients but was given to only two patients as part of long-term therapy. Hypercalcaemic episodes occurring during treatment were of short duration and could be controlled by withdrawal of medication alone.
11名甲状旁腺功能减退患者和2名假性甲状旁腺功能减退患者接受1α-羟基维生素D3治疗长达36个月，血钙水平恢复正常并得以维持。结果发现该化合物效力强大，维持剂量为每周4微克至每日2微克。急性和严重低钙血症患者使用了补充性口服钙剂，但作为长期治疗一部分仅给予了两名患者。治疗期间发生的高钙血症发作持续时间较短，仅通过停药即可控制。
